{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:53:00Z","timestamp":1790232780317,"version":"4.1.0"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,6,20]]},"DOI":"10.18632\/oncotarget.3684","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T02:31:06Z","timestamp":1442284266000},"page":"15332-15347","source":"Crossref","is-referenced-by-count":29,"title":["Inhibition of insulin-like growth factor receptor\/AKT\/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway\n                    <i>in vitro<\/i>\n                    and\n                    <i>in vivo<\/i>"],"prefix":"10.18632","volume":"6","author":[{"given":"Chetna","family":"Sharon","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somesh","family":"Baranwal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmita J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rodriguez-Agudo","sequence":"additional","affiliation":[{"name":"Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA"},{"name":"Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Pandak","sequence":"additional","affiliation":[{"name":"Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA"},{"name":"Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhip P. N.","family":"Majumdar","sequence":"additional","affiliation":[{"name":"John D. Dingell VAMC, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Krystal","sequence":"additional","affiliation":[{"name":"Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA"},{"name":"Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaumik B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA"},{"name":"Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,3,29]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/j.1463-1318.2011.02765.x","article-title":"A systematic review of treatment guidelines for metastatic colorectal cancer","volume":"14","author":"Sykes","year":"2012","journal-title":"Colorectal Dis"},{"key":"2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.2174\/092986709788186147","article-title":"Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance","volume":"16","author":"Russo","year":"2009","journal-title":"Curr Med Chem"},{"key":"3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00063030-200721050-00002","article-title":"Selective targeting of cancer stem cells: a new concept in cancer therapeutics","volume":"21","author":"Wicha","year":"2007","journal-title":"BioDrugs"},{"key":"4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Weissman","year":"2001","journal-title":"Nature"},{"key":"5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/stem.1031","article-title":"Colorectal cancer stem cells","volume":"30","author":"Papavassiliou","year":"2012","journal-title":"Stem Cells"},{"key":"6","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1073\/pnas.0915135107","article-title":"Cancer stem cells from colorectal cancer-derived cell lines","volume":"107","author":"Bodmer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14712598.2011.573780","article-title":"Cancer stem cells: the development of new cancer therapeutics","volume":"11","author":"Giardina","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"8","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.4161\/cc.10.14.16418","article-title":"Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab","volume":"10","author":"El-Deiry","year":"2011","journal-title":"Cell Cycle"},{"key":"9","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/bcr3423","article-title":"The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem\/progenitors","volume":"15","author":"Yu","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","article-title":"Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition","volume":"69","author":"Samuel","year":"2009","journal-title":"Cancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"e86459","DOI":"10.1371\/journal.pone.0086459","article-title":"Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor","volume":"9","author":"Nara","year":"2014","journal-title":"PLoS One"},{"key":"12","first-page":"372","article-title":"Synergy between PI3K\/Akt and Raf\/MEK\/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells","volume":"3","author":"McCubrey","year":"2004","journal-title":"Cell Cycle"},{"key":"13","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Margolick","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14","doi-asserted-by":"crossref","first-page":"e1000121","DOI":"10.1371\/journal.pbio.1000121","article-title":"Regulation of mammary stem\/progenitor cells by PTEN\/Akt\/beta-catenin signaling","volume":"7","author":"Clouthier","year":"2009","journal-title":"PLoS Biol"},{"key":"15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/djs258","article-title":"Insulin-like growth factor receptor inhibitors: baby or the bathwater?","volume":"104","author":"Yee","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"16","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1158\/1078-0432.CCR-12-0489","article-title":"Novel aspects of mevalonate pathway inhibitors as antitumor agents","volume":"18","author":"Gruenbacher","year":"2012","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-2275(20)42221-7","article-title":"Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth","volume":"21","author":"Goldstein","year":"1980","journal-title":"J Lipid Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Brown","year":"1990","journal-title":"Nature"},{"key":"19","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Martirosyan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Barsotti","year":"2012","journal-title":"Cell"},{"key":"21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/stem.1122","article-title":"Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target","volume":"30","author":"Finetti","year":"2012","journal-title":"Stem Cells"},{"key":"22","article-title":"Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop","author":"Trudel","year":"2014","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.23097","article-title":"Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R","volume":"122","author":"Majumdar","year":"2008","journal-title":"Int J Cancer"},{"key":"24","first-page":"319","article-title":"Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R","volume":"30","author":"Majumdar","year":"2010","journal-title":"Anticancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1476-4598-9-212","article-title":"The Wnt\/beta-catenin pathway regulates growth and maintenance of colonospheres","volume":"9","author":"Majumdar","year":"2010","journal-title":"Mol Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.1061803","article-title":"propagation and transcriptional profiling of human mammary stem\/progenitor cells","volume":"17","author":"Wicha","year":"2003","journal-title":"Genes Dev"},{"key":"27","doi-asserted-by":"crossref","DOI":"10.1021\/cb500402f","article-title":"Synthetic, Non-saccharide, Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells","author":"Patel","year":"2014","journal-title":"ACS Chem Biol"},{"key":"28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbamcr.2011.09.017","article-title":"Akt acutely activates the cholesterogenic transcription factor SREBP-2","volume":"1823","author":"Brown","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.00025.2005","article-title":"Transcriptional regulation of metabolism","volume":"86","author":"Wahli","year":"2006","journal-title":"Physiol Rev"},{"key":"30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/cvr\/cvt203","article-title":"Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation","volume":"100","author":"Lv","year":"2013","journal-title":"Cardiovasc Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3892\/or.2013.2819","article-title":"analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer","volume":"31","author":"Chowdhury","year":"2014","journal-title":"Oncol Rep"},{"key":"32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas N","year":"2012","journal-title":"Nature"},{"key":"33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nature12297","article-title":"mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function","volume":"499","author":"Chi","year":"2013","journal-title":"Nature"},{"key":"34","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex","volume":"450","author":"Puigserver","year":"2007","journal-title":"Nature"},{"key":"35","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Bruzek","year":"2007","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1054\/bjoc.2001.1820","article-title":"Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells","volume":"84","author":"Mosca","year":"2001","journal-title":"Br J Cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1389450053765833","article-title":"Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications","volume":"6","author":"Caponigro","year":"2005","journal-title":"Curr Drug Targets"},{"key":"38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Low","year":"2005","journal-title":"N Engl J Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Jakesz","year":"2009","journal-title":"N Engl J Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Gil","year":"2010","journal-title":"Br J Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1182\/blood-2009-07-230508","article-title":"Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma","volume":"115","author":"Jurisica","year":"2010","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/DCR.0b013e3182a4b236","article-title":"Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer","volume":"56","author":"Kalady","year":"2013","journal-title":"Dis Colon Rectum"},{"key":"43","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","article-title":"Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study","volume":"109","author":"Estrov","year":"2007","journal-title":"Blood"},{"key":"44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/FPC.0b013e32834a5585","article-title":"The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action","volume":"21","author":"Rozman","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.cad.0000215058.85813.02","article-title":"Synergistic antimyeloma effects of zoledronate and simvastatin","volume":"17","author":"Meinhardt","year":"2006","journal-title":"Anticancer Drugs"},{"key":"46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12307-013-0129-z","article-title":"Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone","volume":"6","author":"Wikstrom","year":"2013","journal-title":"Cancer Microenviron"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T17:08:21Z","timestamp":1653152901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,29]]},"references-count":46,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,6,20]]}},"alternative-id":["3684","25895029"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3684","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,29]]}}}